Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
HER2 PARADIGM
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
- NCT06750484 ↗
- Recruiting
- Yale University
- Focused
We haven't built an HCP commentary report on HER2 PARADIGM (trastuzumab deruxtecan in Breast Cancer Metastatic) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HER2 PARADIGM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer Metastatic
- Interventions
- Trastuzumab Deruxtecan
- Arms
- Trastuzumab Deruxtecan · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Objective Response Rate
- Sponsor
- Yale University with Daiichi Sankyo, AstraZeneca, Breast Cancer Research Foundation
- Start
- Jun 20, 2025
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06750484 · updated Sep 3, 2026